{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/opioid-dependence/background-information/definition/","result":{"pageContext":{"chapter":{"id":"28447573-cc1d-50d6-bea5-720f6d22e335","slug":"definition","fullItemName":"Definition","depth":2,"htmlHeader":"<!-- begin field d1259366-9919-4391-8db7-5a2997b0d5ae --><h2>What is it?</h2><!-- end field d1259366-9919-4391-8db7-5a2997b0d5ae -->","summary":"","htmlStringContent":"<!-- begin item 85a462d1-cd0d-472c-8e73-6319674fa701 --><!-- begin field 74dbbd57-a6e2-4921-9756-0f25381b913f --><ul><li><strong>An opioid is</strong> either a natural derivative of opium (for example, heroin) or a synthetic substance (for example, methadone, or buprenorphine) with agonist, partial agonist, or mixed agonist and antagonist activity at opioid receptors. </li><li><strong>An opiate is</strong> either a natural derivative or a semi-synthetic constituent of opium. </li><li>The terms 'opioid' and 'opiate' can be considered as largely synonymous, and for the purpose of this CKS topic, the term 'opioid' is used.</li><li><strong>Opioid dependence develops after a period of regular use of opioids</strong>, with the time required varying according to the quantity, frequency and route of administration, factors of individual vulnerability and the context in which drug use occurs. Opioid dependence is not just a heavy use of opioids but a complex health connotation that has social, psychological and biological determinants and consequences, including changes in the brain. It is not a weakness of character or will.<ul><li>Physical and psychological dependence can develop within a relatively short period of continuous use (2–10 days).</li></ul></li><li><strong>The key elements of opioid dependence are:</strong><ul><li>A strong desire or sense of compulsion to take opioids.</li><li>Difficulty in controlling use.</li><li>A physiological withdrawal state when opioid use has ceased or been reduced.</li><li>Evidence of tolerance.</li><li>Progressive neglect of alternative pleasures and interests.</li><li>Persistence with opioid use despite clear evidence of overtly harmful consequences.</li></ul></li><li>Opioid dependence should be viewed as a chronic relapsing-remitting disorder which has physical, social, and psychological dimensions.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">WHO, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">NICE, 2014</a>]</p><!-- end field 74dbbd57-a6e2-4921-9756-0f25381b913f --><!-- end item 85a462d1-cd0d-472c-8e73-6319674fa701 -->","topic":{"id":"ef534296-f504-5d3e-9b47-3c0f08322658","topicId":"1acd30d9-6aea-492b-a570-5fbeb05d49f5","topicName":"Opioid dependence","slug":"opioid-dependence","lastRevised":"Last revised in October 2020","chapters":[{"id":"7b9e0e1a-3aea-5219-a001-dfd22a786292","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0179729-bb50-55a3-a1dc-ca3cbd473972","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e63e1346-068d-56e6-891b-85878800d361","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"37edcefe-2b9f-5ab8-a584-be9e268559ac","slug":"changes","fullItemName":"Changes"},{"id":"b53b49f5-e58d-5325-8fee-7f9fdc057646","slug":"update","fullItemName":"Update"}]},{"id":"242f440f-b9b5-51a4-9d43-3492e963e9af","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5766349b-04fe-548c-9de5-0ff28c7803b9","slug":"goals","fullItemName":"Goals"},{"id":"2ed8ffe3-15a2-5e49-b2ad-033e1a4b5f22","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"419add6c-5149-5bbf-9be1-8854fefbccc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01b28023-8c52-53e9-a23d-43bb73f67990","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e459f916-c763-56aa-9a4e-a3e6ef261b0f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a96bc65-6eb3-5a1c-99c3-2530b6d352f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b1fa8640-11da-554d-9d7a-12696b906136","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28447573-cc1d-50d6-bea5-720f6d22e335","slug":"definition","fullItemName":"Definition"},{"id":"d7f47150-a2c5-57f9-88aa-5353f86fc58a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e594be8-c4df-5032-ad75-87ab56cb2c7e","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7da5320-e6b9-59fc-8e5a-558ea4c298d9","slug":"complications","fullItemName":"Complications"}]},{"id":"e747d7e1-25ca-5f67-9d22-349d2b18eddd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ee9cab5c-4665-56a2-9005-028143cc8f59","slug":"suspecting-opioid-dependency","fullItemName":"Suspecting opioid dependency"},{"id":"20c15a53-634f-5cb4-a88a-7cb5115d810b","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"f37505e6-dc82-5755-b700-7d1966f8c252","fullItemName":"Management","slug":"management","subChapters":[{"id":"75fe82a9-9ba2-541a-80be-cd0cf879bca3","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"d05968e4-f2be-5378-b462-0b129f5dc5e6","slug":"management","fullItemName":"Scenario: Management"},{"id":"00d16467-be2b-538d-8a7c-4d4045cabd6e","slug":"managing-special-circumstances","fullItemName":"Scenario: Managing special circumstances"}]},{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ccbe88d0-314a-57fa-a61a-8a83bbfc9baf","slug":"writing-prescriptions-for-substitution-therapy","fullItemName":"Writing prescriptions for substitution therapy"},{"id":"5c859eeb-d8fd-50f5-8b18-e1a6a71ac111","slug":"methadone","fullItemName":"Methadone"},{"id":"3021db45-0a93-5ca8-a386-8d3e71abad63","slug":"buprenorphine","fullItemName":"Buprenorphine"}]},{"id":"9547692f-53b7-5f09-944d-6a4a6229dead","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0eafd778-db7f-578e-905f-1365ee1290a1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d80b232-8932-503b-8765-30b929f15180","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"796c8942-47b7-56b5-a88a-cc0f133f5f3e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfb530c5-aa05-5f4c-9e26-43caae839601","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"955b9fba-573b-57a0-b099-cf3356d6e837","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f05fac2-c160-5e48-b55d-3898cce03ec0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0ead7d6b-f923-5852-bb7c-50aa97b9b2ff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b1fa8640-11da-554d-9d7a-12696b906136","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}